Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewCG 428 is a potent tropomyosin receptor kinase (TRK) Degrader (uSMITE™) (DC50 = 0.36 nM). CG 428 comprises an analog of the pan-TRK inhibitor GNF-8625 joined by a linker to the cereblon E3 ligase ligand pomalidomide (Cat. No. 6302). CG 428 shows selectivity for TRKA over TRKC and TRKB (Kd values = 1nM, 4.2 nM and 28 nM, respectively). Inhibits growth of KM12 colon cancer cells (IC50 =2.9 nM) and is bioavailable.
Negative control CG 428-Neg (Cat. No. 7426), and TrkB antibodies validated for Simple Western™ (automated Western) instruments and Western Blot also available: Catalog # AF1494 and AF397.
Sold under license from Cullgen
E3 ligase | CRBN |
DC50 | 0.36 nM (TMP3-TRKA), 2.23 nM (TRKA) - Degradation in KM12/HEL cells after 6 h treatment |
Kd (Degrader to Target) | 1 nM - Kd was assessed using the KINOMEscan assay |
IC50 (Cellular Activity) | 2.9 nM - Inhibits growth of KM12 cells |
Selectivity confirmed by global proteomics | No |
分子量 | 814.88 |
公式 | C43H43FN10O6 |
储存 | Store at -20°C |
纯度 | ≥98% (HPLC) |
CAS Number | 2412055-93-5 |
PubChem ID | 146410727 |
InChI Key | FWANKJAOTQAHHR-KWRHIPAJSA-N |
Smiles | FC1=CC=CC([C@H]2CCCN2C3=NN4C(C=C3)=NC=C4C5=NC(N6CCN(C(CCOCCNC7=C8C(N(C(C8=CC=C7)=O)C9CCC(NC9=O)=O)=O)=O)CC6)=CC=C5)=C1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
DMSO | 81.49 | 100 |
以下数据基于产品分子量 814.88。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.23 mL | 6.14 mL | 12.27 mL |
5 mM | 0.25 mL | 1.23 mL | 2.45 mL |
10 mM | 0.12 mL | 0.61 mL | 1.23 mL |
50 mM | 0.02 mL | 0.12 mL | 0.25 mL |
参考文献是支持产品生物活性的出版物。
Chen et al (2020) Discovery of first-in-class potent and selective tropomyosin receptor kinase degraders. J.Med.Chem. 63 14562 PMID: 33058680
If you know of a relevant reference for CG 428, please let us know.
关键词: CG 428, CG 428 supplier, CG428, degraders, uSMITE, E3, ligase, TRK, tropomyosin, receptors, kinases, potent, selective, PROTAC, targeted, protein, degradation, Ubiquitin-mediated, Small, Molecule-Induced, Target, Elimination, Other, Kinases, Raf, and, Ras, Degraders, 7425, Tocris Bioscience
目前没有该产品的评论。 Be the first to review CG 428 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
This brochure highlights the tools and services available from Bio-Techne to support your Targeted Protein Degradation and Induced Proximity research, including:
Written by Kirsten L. Bryant, Adrienne D. Cox and Channing J. Der, this review provides a comprehensive overview of RAS protein function and RAS mutations in cancer. Key signaling pathways are highlighted and therapeutic vulnerabilities are explored. This review also includes a detailed section on RAS drug discovery and targeting synthetic lethal interactors of mutant RAS. Compounds available from Tocris are listed.
Degraders (e.g. PROTACs) are bifunctional small molecules, that harness the Ubiquitin Proteasome System (UPS) to selectively degrade target proteins within cells. They consist of three covalently linked components: an E3 ubiquitin ligase ligand, a linker and a ligand for the target protein of interest. Authored in-house, this poster outlines the generation of a toolbox of building blocks for the development of Degraders. The characteristics and selection of each of these components are discussed. Presented at EFMC 2018, Ljubljana, Slovenia